TickerFacts.

Immunocore Holdings plc (IMCR): Cost of Revenue

Annual figures by period end, from SEC filings.

$5.09M
Year ended 2025-12-31
$4.74M
Trailing 12 months to 2026-06-30
+67.2%
3-year compound annual growth
2021-12-31: $02022-12-31: $1.09M2023-12-31: $1.04M2024-12-31: $2.73M2025-12-31: $5.09M$5.09M
2021-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$5.09M+86.3%2026-02-25, From 2025-01-01
2024-12-31$2.73M+163.4%2026-02-25, From 2024-01-01
2023-12-31$1.04M-4.8%2026-02-25, From 2023-01-01
2022-12-31$1.09Mn/a2025-02-26, From 2022-01-01
2021-12-31$0n/a2024-02-28, From 2021-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Immunocore Holdings plc (IMCR)2025-12-31$5.09M+86.3%
Twist Bioscience Corp (TWST)2025-09-30$185.57M+3.3%
ADMA Biologics, Inc. (ADMA)2025-12-31$217.41M+5.1%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$71.36M-1.0%
Vericel Corp (VCEL)2025-12-31$70.66M+8.5%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$173.18M+85.7%
Repligen Corp (RGEN)2025-12-31$352.01M-2.2%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$19.07M+55.5%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$70.0Kn/a

Compare IMCR, TWST, ADMA, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗